Patents Issued in October 12, 2017
  • Publication number: 20170291858
    Abstract: An assemblable appliance and method of recycling organic waste into biogas and liquid fertilizer, implementing essentially anaerobic digestion processes, is described. The assemblable appliance includes: a pliant structured exoskeletal envelope, pliable collapsible anaerobic digester and gas tank. A compact kit-of-parts for assembling the aforementioned appliance and respective method using the aforementioned appliance for recycling organic waste into biogas and liquid fertilizer are described.
    Type: Application
    Filed: June 25, 2017
    Publication date: October 12, 2017
    Applicant: HOME BIOGAS LTD
    Inventors: Oshik Moshe EFRATI, Yair TELLER, Erez LANZER, Shoham ZAK
  • Publication number: 20170291859
    Abstract: The invention concerns a process for the production of butadiene from an ethanol feed comprising at least 80% by weight of ethanol, comprising at least one step A) for the conversion of ethanol into acetaldehyde A), a step B) for converting an ethanol/acetaldehyde mixture into butadiene, a step C1) for hydrogen treatment, a step D1) for butadiene extraction, a first butadiene purification step D2), a subsequent butadiene purification step D3), an effluent treatment step E1), a step E2) for eliminating impurities and brown oils and a step F) for scrubbing with water.
    Type: Application
    Filed: September 17, 2015
    Publication date: October 12, 2017
    Applicants: IFP Energies nouvelles, Compagnie Generale des Etablissements Michelin, MICHELIN RECHERCHE ET TECHNIQUE S.A.
    Inventors: Rejane DASTILLUNG, Beatrice FISCHER, Marc JACQUIN, Raphael HUYGHE
  • Publication number: 20170291860
    Abstract: Apparatus and methods are provided for converting methane in a feed stream to acetylene. A hydrocarbon stream is introduced into a supersonic reactor and pyrolyzed to convert at least a portion of the methane to acetylene. The reactor effluent stream may be treated to convert acetylene to another hydrocarbon process.
    Type: Application
    Filed: June 21, 2017
    Publication date: October 12, 2017
    Inventors: Robert L. Bedard, Christopher Naunheimer, Gavin P. Towler, Laura E. Leonard, Rodolphe Dudebout, Gregory O. Woodcock, Donald L. Mittendorf, Aziz Sattar, Christopher D. Gatto, Robert S. Murray
  • Publication number: 20170291861
    Abstract: Apparatus and methods are provided for converting methane in a feed stream to acetylene. A hydrocarbon stream is introduced into a supersonic reactor and pyrolyzed to convert at least a portion of the methane to acetylene. The reactor effluent stream may be treated to convert acetylene to another hydrocarbon process.
    Type: Application
    Filed: June 22, 2017
    Publication date: October 12, 2017
    Inventors: Robert L. Bedard, Christopher Naunheimer, Gavin P. Towler, Laura E. Leonard, Gregory O. Woodcock, Donald L. Mittendorf, Aziz Sattar, Christopher D. Gatto, Robert S. Murray
  • Publication number: 20170291862
    Abstract: A method for producing at least one olefin compound selected from the group consisting of a compound of formula (51), a compound of formula (52), a compound of formula (53), and a compound of formula (54), the method including reacting an olefin compound of formula (21) with a olefin compound of formula (31) in the presence of at least one metal catalyst selected from the group consisting of a compound of formula (11), a compound of formula (12), a compound of formula (13), a compound of formula (14), and a compound of formula (15).
    Type: Application
    Filed: June 26, 2017
    Publication date: October 12, 2017
    Applicant: ASAHI GLASS COMPANY, LIMITED
    Inventor: Yusuke TAKAHIRA
  • Publication number: 20170291863
    Abstract: A method for producing at least one olefin compound selected from the group consisting of a compound of formula (51) and a compound of formula (52), the method including reacting an olefin compound of formula (21) with a olefin compound of formula (31) in the presence of at least one metal catalyst selected from the group consisting of a compound of formula (11), a compound of formula (12), a compound of formula (13), a compound of formula (14), and a compound of formula (15).
    Type: Application
    Filed: June 26, 2017
    Publication date: October 12, 2017
    Applicant: ASAHI GLASS COMPANY, LIMITED
    Inventors: Yusuke TAKAHIRA, Daisuke JOMUTA
  • Publication number: 20170291864
    Abstract: A method includes brominating a butanes feed stream including i-butane in a bromination reactor to form a bromination effluent stream including t-butyl bromide. The method includes dehydrobrominating the t-butyl bromide to form isobutylene. Another method includes brominating a mixed pentanes feed stream including i-pentane and n-pentane in a bromination reactor to form a bromination effluent stream including t-pentyl bromide. The method includes dehydrobrominating the t-pentyl bromide to form isoamylene and HBr.
    Type: Application
    Filed: September 15, 2015
    Publication date: October 12, 2017
    Inventors: Jeffrey H. Sherman, Peter K. Stoimenov
  • Publication number: 20170291865
    Abstract: A polyfluoroalkyl allyl compound represented by the general formula: CF3(CF2)n(CH2CF2)a(CF2CF2)bCH2CH?CH2??[I] (n: 0 to 5, a: 1 or 2, b: 0 to 3). The polyfluoroalkyl allyl compound is produced by reacting a carboxylic acid allyl adduct represented by the general formula: CF3(CF2)n(CH2CF2)a(CF2CF2)bCH2CHICH2OCOR???[II] (n, a, and b are as defined above, and R?: a C1-C3 alkyl group) with a transition metal. This method for producing provides a polyfluoroalkyl allyl compound used as a synthetic intermediate for a fluorine-containing alkylsilane compound that can remove free iodine derived from the raw material compound, before a hydrosilylation reaction is performed, without using a metal reagent having a high environmental impact, and that has excellent handling properties.
    Type: Application
    Filed: September 18, 2015
    Publication date: October 12, 2017
    Applicant: UNIMATEC CO., LTD.
    Inventor: Takeshi FUKUSHIMA
  • Publication number: 20170291866
    Abstract: A method for producing mixed aldol products from the products of hydroformylation reactions. In one embodiment, the method comprises mixing hydroformylation reaction products comprising aldehydes with a catalyst inside a reactor to create a mixture. The method also includes agitating the mixture at a temperature in a range of between about 200° F. to about 275 ° F. to create a reacted mixture. The reacted mixture is then cooled in the reactor to create an organic phase and an aqueous phase. The organic phase is pumped out of the reactor and may then be transferred to a distillation tower. The organic phase may be distilled until any mixed aldol products are isolated, wherein the mixed aldol products may be subsequently removed.
    Type: Application
    Filed: June 26, 2017
    Publication date: October 12, 2017
    Applicant: Texmark Chemicals, Inc.
    Inventors: Rajeshwari Kannan, Rebecca L. Rosas
  • Publication number: 20170291867
    Abstract: A process for ring hydrogenation of a benzenepolycarboxylic acid or derivative thereof, includes contacting a feed stream comprising the acid or derivative thereof with a hydrogen containing gas in the presence of a catalyst under hydrogenation conditions to produce a hydrogenated product, wherein the catalyst contains rhodium and ruthenium.
    Type: Application
    Filed: October 9, 2015
    Publication date: October 12, 2017
    Inventors: Stuart L. Soled, Sabato Miseo, Joseph E. Baumgartner, Christine E. Kliewer, Hans K. T. Goris
  • Publication number: 20170291868
    Abstract: The invention includes a diester exhibiting improved hydrolytic stability that is an esterification product of a 1-methylheptyl alcohol and a dicarboxylic acid. In some embodiments, the diester is bis(1-methyl heptyl) butanedioate, bis(1-methyl heptyl) nonanedioate and/or bis(1-methyl heptyl) decanedioate. The diester may be natural and/or not sourced from palm. Also contemplated within the scope of the invention are diesters exhibiting improved hydrolytic stability represented by Formula (I): wherein R1 is chosen from a linear alkyl group containing four to ten carbon atoms.
    Type: Application
    Filed: April 7, 2017
    Publication date: October 12, 2017
    Inventors: Rocco Burgo, Daniel Winn
  • Publication number: 20170291869
    Abstract: The invention relates to a method for producing dinitrotoluene, comprising the following steps: a) nitrating toluene with a mixture of nitric acid and sulfuric acid and subsequently separating a sulfuric-acid-containing aqueous phase that arises in the nitration, wherein a raw dinitrotoluene is obtained, b) washing the raw dinitrotoluene in a water wash with neutral and/or alkaline washing water, wherein a pre-cleaned dinitrotoluene, which contains at least water in addition to dinitrotoluene, is obtained after the washing water used in the last wash has been separated, and c) separating the water from the pre-cleaned dinitrotoluene, d) collecting the waste water from steps a), b), and/or c), e) optionally extracting the collected waste water from step d) with toluene and returning the thus obtained organic phase to step a), f) freeing the collected waste water from step d), or, if the optional step e) is performed, the extracted waste water from step e), of toluene in a toluene stripper, wherein a toluene-co
    Type: Application
    Filed: September 29, 2015
    Publication date: October 12, 2017
    Inventors: Thomas KNAUF, Jürgen MÜNNIG, Wolfgang LORENZ, Bernd PENNEMANN
  • Publication number: 20170291870
    Abstract: The present invention relates to an amide compound solution comprising an amide compound and a surfactant. More specifically, the invention relates to an amide compound solution comprising amide compound, and 2.7˜20 mg of a cationic surfactant per 1 kg of the amide compound or 0.01˜10 mg of a C15˜C20 carboxylic acid or its salt as an anionic surfactant per 1 kg of the amide compound. The present invention provides an amide compound solution which is manufactured using a biocatalyst and which has a low level of foaming, and thereby improving the operability and yield when manufacturing an amide compound-based polymer.
    Type: Application
    Filed: February 15, 2016
    Publication date: October 12, 2017
    Applicant: Mitsubishi Rayon Co., Ltd.
    Inventors: Makoto KANO, Norifumi HAGIYA
  • Publication number: 20170291871
    Abstract: Novel 2,2?-diaminobiaryls having one primary and one secondary amine and an electrochemical process for preparation thereof.
    Type: Application
    Filed: July 23, 2015
    Publication date: October 12, 2017
    Applicant: EVONIK DEGUSSA GMBH
    Inventors: Katrin Marie DYBALLA, Robert FRANKE, Dirk FRIDAG, Siegfried R. WALDVOGEL, Bernd ELSLER, Mathias ENDERS
  • Publication number: 20170291872
    Abstract: Compositions comprising branched C10 mercaptans selected from the group consisting of 5-methyl-1-mercapto-nonane, 3-propyl-1-mercapto-heptane, 4-ethyl-1-mercapto-octane, 2-butyl-1-mercapto-hexane, 5-methyl-2-mercapto-nonane, 3-propyl-2-mercapto-heptane, 4-ethyl-2-mercapto-octane, 5-methyl-5-mercapto-nonane, and combinations thereof.
    Type: Application
    Filed: June 26, 2017
    Publication date: October 12, 2017
    Inventors: Michael S. Matson, Jim D. BYERS, Jason L. KREIDER
  • Publication number: 20170291873
    Abstract: A process includes reacting, in a reactor having a fixed bed containing a solid catalyst which contains a heterogeneous ion exchange resin, hydrogen sulfide and ethylene oxide in the presence of the solid catalyst to yield a reaction product which contains beta-mercaptoethanol. A reactor system includes the reactor, an ethylene oxide stream, a hydrogen sulfide stream, a fixed bed containing the solid catalyst placed in the reactor, and an effluent stream containing the reaction product. During steady state operation of the reactor in the process and the reactor system, the hydrogen sulfide and the ethylene oxide are present in a mole ratio in a range of about 9:1 to about 20:1.
    Type: Application
    Filed: June 26, 2017
    Publication date: October 12, 2017
    Inventors: Daniel M. HASENBERG, Alex PAUWELS
  • Publication number: 20170291874
    Abstract: The present invention relates to the preparation of N-(2-(6-fluoro-1H-indol-3-yl)-ethyl)-3-(2,2,3,3-tetrafluoropropoxy)-benzylamine (Compound I), INN-name idalopirdine, and pharmaceutically acceptable salts thereof:
    Type: Application
    Filed: April 6, 2017
    Publication date: October 12, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Mikkel Fog Jacobsen, Florian Anton Martin Huber
  • Publication number: 20170291875
    Abstract: The present invention provides compounds of formula (I) as described herein and pharmaceutically acceptable salts, hydrates and solvates thereof for use in medicine, for example in the treatment of acute myeloid leukaemia:
    Type: Application
    Filed: August 28, 2015
    Publication date: October 12, 2017
    Inventors: Paul Vincent Fish, Niall Igoe, Elliott David Bayle
  • Publication number: 20170291876
    Abstract: A synthesis method of ?-nitropyrazole amide compound through asymmetrical catalyzing technique is provided, a nitroalkane and an ?,?-unsaturated pyrazole amide are applied as the raw material, a complex formed by a chiral amine oxide with a rare earth metal compound is served as the catalyst, a 4 ? molecular sieve is served as an additive, the ?-nitropyrazole amide compound can be obtained with a yield more than 99% and enantiomeric excess more than 99% ee. The catalytic system not only has the advantages of simple operation, mild reaction conditions, requiring no acid/base additives, convenient product purification, high yield and enatioselectivity, compliance with green atomic economy, and promising prospects for industrial application, but also allows the obtained ?-nitropyrazole amide compound to undergo some simple chemical conversions to produce some molecules having physiological activities.
    Type: Application
    Filed: June 12, 2015
    Publication date: October 12, 2017
    Inventors: Xiaoming FENG, Qian YAO, Xiaohua LIU, Lili LIN, Yuheng ZHANG
  • Publication number: 20170291877
    Abstract: The present invention relates to antimicrobial imidazolium compounds having the structure of Formula (I) wherein R is an optionally substituted aliphatic group that is linear, cyclic, saturated, unsaturated or any combination thereof; n is an integer of at least 1; and X is an anionic counterion. The present invention also relates to pharmaceutical composition comprising the compound, a gel comprising the compound, uses of the compound as an antibiotic and methods for the preparation of the gels.
    Type: Application
    Filed: September 15, 2015
    Publication date: October 12, 2017
    Inventors: Yugen ZHANG, Siti Nurhanna Binti RIDUAN, Yuan YUAN
  • Publication number: 20170291878
    Abstract: A method for producing a compound (3), which comprises allowing a compound (1) to react with hydrogen gas in an inert solvent, in the presence of a specific chiral ligand and a ruthenium catalyst, or in the presence of an asymmetric transition metal complex catalyst previously generated from the chiral ligand and the ruthenium catalyst.
    Type: Application
    Filed: September 17, 2015
    Publication date: October 12, 2017
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Tsuyoshi UEDA, Kazutoshi UKAI
  • Publication number: 20170291879
    Abstract: A cancer cell proliferation inhibitor including at least one selected from compounds represented by Structural Formulae (1) to (8), wherein the cancer cell is at least one of a cancer cell overexpressing a wild-type epidermal growth factor receptor and a cancer cell expressing an epidermal growth factor receptor mutant vIII.
    Type: Application
    Filed: September 7, 2015
    Publication date: October 12, 2017
    Inventors: Sonoko Atsumi, Masabumi Shibuya, Shun-ichi Ohba, Tomoyuki Kimura, Yoshihiko Kobayashi, Hayamitsu Adachi, Chisato Nosaka, Akio Nomoto
  • Publication number: 20170291880
    Abstract: Disclosed is a process for the preparation of toltrazuril of formula (I) via the intermediate N-methyl-N?-[3-methyl-4-[4-[(trifluoromethyl)thio]phenoxy]phenyl] imidodicarbonic diamide of formula (III) wherein intermediate (III) is obtained via a novel intermediate without the use of potentially hazardous reagents or potentially unstable intermediates.
    Type: Application
    Filed: April 6, 2017
    Publication date: October 12, 2017
    Inventors: Massimo Ferrari, Daniele De Zani, Matteo Bonaldi
  • Publication number: 20170291881
    Abstract: Methods of synthesizing 2-(1?H-indole-3?-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) and structural analogs thereof. The methods include condensation reactions or condensation and oxidation reactions to form the thiazoline or thiazole moiety of ITE or its structural analogs.
    Type: Application
    Filed: September 10, 2015
    Publication date: October 12, 2017
    Applicant: AhR Pharmaceuticals, Inc.
    Inventors: Jiasheng Song, Suoming Zhang, Guodong Li, Luqing Yang
  • Publication number: 20170291882
    Abstract: Solid forms of Mirabegron, including forms APO-I, APO-II, and various salt forms, and processes for the preparation thereof, are provided.
    Type: Application
    Filed: October 1, 2015
    Publication date: October 12, 2017
    Inventors: Allan W. Rey, Annyt Bhattacharyya, Jenny L. Gerster, Sammy Chris Duncan, Mohammed Abdul Raheem, Fan Wang, Stuart P. Green
  • Publication number: 20170291883
    Abstract: It is an object of the present invention to provide a medicament for preventing or treating hyperphosphatemia. The solution is crystals, or hydrate thereof, of a salt of a compound represented by formula (I).
    Type: Application
    Filed: September 18, 2015
    Publication date: October 12, 2017
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Mizuka YOKOYAMA, Yasusi UEDA, Daisuke FUKATSU, Yuichi AKI
  • Publication number: 20170291884
    Abstract: The present invention relates to novel compounds and their use as malodor counteractant materials.
    Type: Application
    Filed: September 25, 2015
    Publication date: October 12, 2017
    Applicant: International Flavors & Fragrances Inc.
    Inventors: Sean M. Wetterer, Drew T. Parkhurst, Richard Anthony Weiss, Anthony T. Levorse, Jr., Michael G. Monteleone, Richard M. Boden
  • Publication number: 20170291885
    Abstract: Provided is a method for preparing an enamide compound, which includes reacting an organic azide compound having ?-hydrogen and an anhydride by addition of a ruthenium complex catalyst in the presence of an ionic liquid, and a ruthenium complex catalyst used herein.
    Type: Application
    Filed: March 30, 2017
    Publication date: October 12, 2017
    Inventors: Jai Wook PARK, Jin Yong PARK, Yong Jin KIM, Yea Rang KWON, Han Kyu PAK, Young Ho RHEE
  • Publication number: 20170291886
    Abstract: The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a protozoan infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a protozoan infection in a subject and to a medical device comprising the composition of the invention.
    Type: Application
    Filed: August 28, 2015
    Publication date: October 12, 2017
    Inventors: Stephen Page, Andrew Stevens, Adam McCluskey, Martine Keenan, Rebecca Abraham
  • Publication number: 20170291887
    Abstract: Filamenting temperature-sensitive mutant Z (FtsZ) protein plays a crucial role in the bacterial cell division machinery and is a validated drug target for antibacterial agents. The present invention relates to FtsZ-interacting compounds that possess a 2,4,6-trisubstituted pyrimidine scaffold. Some of these compounds possess potent anti-staphylococcal properties and potent antibacterial activities against clinically isolated MRSA strains. Compounds have been identified to exhibit low spontaneous frequency of resistance, low toxicity as well as the ability to rescue G. mellonella larvae infected with lethal dose of the MRSA ATCC 43300 strain. Characterization by saturation transfer difference NMR, light scattering assay and GTPase hydrolysis assay with purified S. aureus FtsZ protein verified the interaction of 2,4,6-trisubstituted pyrimidine with the FtsZ protein, further confirmed by observations of iconic filamentous cell phenotype and mislocalization of the Z-ring formation.
    Type: Application
    Filed: September 29, 2016
    Publication date: October 12, 2017
    Inventors: Kwok-yin WONG, Tak-Hang CHAN, Kin-Fai CHAN
  • Publication number: 20170291888
    Abstract: According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A21, or, particularly, the A2, receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocylic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, whic
    Type: Application
    Filed: November 4, 2016
    Publication date: October 12, 2017
    Inventors: Miles Stuart Congreve, Stephen Philippe Andrews, Jonathan Stephen Mason, Christine Mary Richardson, Giles Albert Brown
  • Publication number: 20170291889
    Abstract: Compounds are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
    Type: Application
    Filed: September 16, 2015
    Publication date: October 12, 2017
    Applicant: IRONWOOD PHARMACEUTICALS, INC.
    Inventors: Timothy Claude BARDEN, James Edward SHEPPECK, Glen Robert RENNIE, Paul Allan RENHOWE, Nicholas PERL, Takashi NAKAI, Ara MERMERIAN, Thomas Wai-Ho LEE, Joon JUNG, James JIA, Karthik IYER, Rajesh R. IYENGAR, G-Yoon Jamie IM
  • Publication number: 20170291890
    Abstract: The present disclosure relates to heterocycle substituted amino-pyridine compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: September 17, 2015
    Publication date: October 12, 2017
    Inventor: John Emmerson Campbell
  • Publication number: 20170291891
    Abstract: The invention concerns novel substituted pyridine-piperazinyl analogues of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Application
    Filed: June 23, 2017
    Publication date: October 12, 2017
    Inventors: Jerôme Emile Georges GUILLEMONT, David Francis Alain LANÇOIS, Magali Madeleine Simone MOTTE, Delphine Yvonne Raymonde LARDEAU, Xavier Marc BOURDREZ, Wendy Mia Albert BALEMANS, Dirk André Emmy ROYMANS
  • Publication number: 20170291892
    Abstract: The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
    Type: Application
    Filed: September 22, 2015
    Publication date: October 12, 2017
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Susanne RÖHRIG, Eloisa JIMENEZ-NUNEZ, Karl-Heinz SCHLEMMER, Adrian TERSTEEGEN, Henrik TELLER, Alexander HILLISCH, Stefan HEITMEIER, Martina Victoria SCHMIDT, Jens ACKERSTAFF, Jan STAMPFUß
  • Publication number: 20170291893
    Abstract: The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.
    Type: Application
    Filed: June 27, 2017
    Publication date: October 12, 2017
    Inventors: Daniel A. Lawrence, Cory Emal, Ashley Reinke, Shih-Hon Li, Mark Warnock, Gregory Abernathy
  • Publication number: 20170291894
    Abstract: The present invention relates to novel compounds of formula (I), process for preparation of the same and composition comprising these compounds.
    Type: Application
    Filed: April 4, 2017
    Publication date: October 12, 2017
    Inventors: Rakesh Ishwar Patil, Jeevan Verma, Puneet Kumar, Amol Pandurang Gunjal, Himanshu Rai, Santosh Kumar Rai, Anil Kumar
  • Publication number: 20170291895
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: June 15, 2017
    Publication date: October 12, 2017
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • Publication number: 20170291896
    Abstract: Disclosed are a compound of formula (I), a tautomer, an optical isomer or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the above-mentioned compounds. The above-mentioned compounds have the activity of inhibiting Xa factor positive effect, and can be used for the preparation of a medicament for preventing and/or treating diseases inhibiting Xa factor positive effect in case of low bleeding risk.
    Type: Application
    Filed: September 2, 2015
    Publication date: October 12, 2017
    Inventors: Ying SHI, Qingzhi GAO, Yi MI, Xuliang WANG
  • Publication number: 20170291897
    Abstract: The present invention relates to compounds that are inhibitors of the orexin-1 receptor. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with orexin-1 receptor activity.
    Type: Application
    Filed: September 3, 2015
    Publication date: October 12, 2017
    Inventors: Emma Louise Blaney, Barrie Phillip Martin, Thorsten Nowak, Martin John Watson
  • Publication number: 20170291898
    Abstract: The present invention provides a life-extending agent comprising pyrroloquinoline quinone and/or a derivative of the pyrroloquinoline quinone.
    Type: Application
    Filed: September 18, 2015
    Publication date: October 12, 2017
    Applicants: National University Corporation Nagoya University, Mitsubishi Gas Chemical Company, Inc.
    Inventors: Ikue MORI, Hiroyuki SASAKURA, Kazuto IKEMOTO, Masahiko NAKANO
  • Publication number: 20170291899
    Abstract: A compound of formula (I) or a salt thereof: wherein R1 represents a five-membered aromatic heterocycle selected from a N- or a C-linked mono- or di-substituted pyrazole, an N- or a C-linked optionally mono- or di-substituted triazole or an N- or a C-linked optionally mono- or di-substituted imidazole, which five-membered aromatic heterocycle may be substituted by one or two of the groups selected a methyl group, an ethyl group, a fluorine atom, a hydroxymethyl group, a 2-hydroxypropan-2-yl group, a trifluoromethyl group, a difluoromethyl group or a fluoromethyl group, except that when R1 represents an N-linked mono- or di-substituted pyrazole, Ri does not represent 3,5-Dimethyl-1H-pyrazol-1-yl, 5-Methyl-1H-pyrazol-1-yl, 5-Ethyl-3-methyl-1H-pyrazol-1-yl, 3,5-Diethyl-1H-pyrazol-1-yl, 4-Fluoro-3,5-dimethyl-1H-pyrazol-1-yl, 3-Methyl-1H-pyrazol-1-yl or 1H-pyrazol-1-yl.
    Type: Application
    Filed: September 22, 2015
    Publication date: October 12, 2017
    Inventors: Niall Andrew ANDERSON, Ian Baxter CAMPBELL, Matthew Howard James CAMPBELL-CRAWFORD, Ashley Paul HANCOCK, Seble LEMMA, Simon John Fawcett MACDONALD, John Martin PRITCHARD, Panayiotis Alexandrou PROCOPIOU
  • Publication number: 20170291900
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: June 27, 2017
    Publication date: October 12, 2017
    Inventors: Ben C. ASKEW, Richard W. HEIDEBRECHT, Takeru FURUYA, Mark E. DUGGAN, D. Scott EDWARDS
  • Publication number: 20170291901
    Abstract: The present invention provides 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Application
    Filed: April 6, 2017
    Publication date: October 12, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Karsten Juhl, Mikkel Jessing, Morten Langgård, Paulo Jorge Vieira Vital, Mauro Marigo, Jan Kehler, Lars Kyhn Rasmussen
  • Publication number: 20170291902
    Abstract: The present patent application discloses at least the compounds according to Formula I? shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, ring F, JB, n, JD, o, RC1, RC2, W, JE, r, JF, s, Z1, Z2 and Z3 are as defined herein.
    Type: Application
    Filed: September 16, 2015
    Publication date: October 12, 2017
    Applicant: IRONWOOD PHARMACEUTICALS, INC.
    Inventors: Nicholas PERL, Takashi NAKAI, Thomas Wai-Ho LEE, Glen Robert RENNIE, Paul Allan RENHOWE, Rajesh R. IYENGAR
  • Publication number: 20170291903
    Abstract: The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Application
    Filed: June 6, 2017
    Publication date: October 12, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård, Mikkel Jessing, Paulo Jorge Vieira Vital, Karsten Juhl
  • Publication number: 20170291904
    Abstract: The subject matter generally relates to compounds and methods of treatment and/or prophylaxis of CNS diseases, disorders, and/or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and/or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.
    Type: Application
    Filed: September 17, 2015
    Publication date: October 12, 2017
    Inventors: Peng LI, Hailin ZHENG, Jun ZHAO, Lawrence WENNOGLE
  • Publication number: 20170291905
    Abstract: Described herein are compounds of Formula (S-I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.
    Type: Application
    Filed: September 17, 2015
    Publication date: October 12, 2017
    Applicant: Epizyme, Inc.
    Inventors: Richard Chesworth, Lorna Helen Mitchell, John Emmerson Campbell, Lawrence Alan Reiter, Kerren Kalai Swinger
  • Publication number: 20170291906
    Abstract: Compounds of formula III: and salts thereof are disclosed. Also disclosed are methods for preparing compounds of formula III, intermediates useful for preparing compounds of formula III and methods for preparing compounds and materials from compounds of formula III.
    Type: Application
    Filed: March 30, 2017
    Publication date: October 12, 2017
    Inventors: Thomas R. Hoye, Ashok Pehere, Shu Xu
  • Publication number: 20170291907
    Abstract: Compounds of formula (I) are A2B receptor antagonists: Wherein R1 is optionally substituted aryl or an optionally substituted 5- or 6-membered heteroaryl ring; R2 and R3 are independently selected from hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl-(C1-C6)-alkyl, aryl-(C1-C6)-alkyl optionally substituted in the ring part thereof, a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C1-C6 alkylene chain and optionally substituted in the ring part thereof, benzimidazol-2-yl-methyl, pyrid-3-yl-carbonyl, or (1-methyl-piperidin-4-yl)-carbonyl-methyl; or R2 and R3 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; R4 is C1-C3 alkyl, C2-C3 alkenyl, —N(—R5)—R6, or optionally substituted heteroarylmethylamino; and R5 and R6 are independently selected from hydrogen or C1-C3 alkyl; or R5 and R6 taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered saturated rin
    Type: Application
    Filed: February 20, 2017
    Publication date: October 12, 2017
    Inventors: Allan Jordan, Simon Bedford, Klenke Burkhard, Ian Yule, Karine Poullennec